Related Experiment Video

Updated: May 12, 2026

Isolation of Neonatal Extrahepatic Cholangiocytes
07:54

Isolation of Neonatal Extrahepatic Cholangiocytes

Published on: June 5, 2014

TPN cholestasis in infants: what do we know? Review

M Hendaus1

  • 1Hamad Medical Corporation, Department of Pediatrics, Doha, Qatar.

Georgian Medical News
|April 10, 2013
PubMed

Insights

Total Parenteral Nutrition (TPN) cholestasis is a growing epidemic in premature infants. Targeting specific receptors and using supplements like Omega-3 may offer protective benefits against this condition.

Area of Science:

  • Hepatology
  • Neonatology
  • Molecular Biology

Background:

  • Cholestasis, a condition of reduced bile flow, is increasingly observed in infants receiving Total Parenteral Nutrition (TPN).
  • Rising survival rates in premature infants have led to a higher incidence of TPN-associated cholestasis, posing a significant clinical challenge.

Purpose of the Study:

  • To provide a comprehensive overview of TPN-associated cholestasis, including its definition, incidence, risk factors, and pathogenesis.
  • To elucidate the molecular mechanisms underlying hepatobiliary transport and bile acid regulation in the context of TPN.
  • To discuss current and future management strategies for TPN cholestasis.

Main Methods:

  • Literature search of PubMed using keywords: "Molecular basis of cholestasis" and "management".
  • Inclusion of relevant information from expert-authored textbooks on the subject.
  • Synthesis of information covering molecular, cellular, and clinical aspects of TPN cholestasis.

Main Results:

  • TPN cholestasis in infants is identified as a major epidemic.
  • Key molecular targets for pharmacological intervention include potent agonists for the Constitutive Androstane Receptor (CAR) and Pregnane X Receptor (PXR).
  • Glutamine, Omega-3 fatty acids, and soybean oil show potential protective effects against TPN cholestasis.

Conclusions:

  • TPN cholestasis represents a critical health issue in neonatal care.
  • Future therapeutic strategies should focus on modulating CAR and PXR pathways.
  • Further research, particularly randomized controlled trials, is essential to validate the protective roles of glutamine, Omega-3, and soybean oil.

More Related Videos

Creation of Reversible Cholestatic Rat Model09:39

Creation of Reversible Cholestatic Rat Model

Published on: May 21, 2011

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...